Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy score of Gleason 8 (GS8) (Grade group 4 \[GG4\]) or higher. Patients also need to have a positive PSMA scan on 68-Ga-PSMA-11 PET/CT scan.

Trial Details

NCT ID
NCT06798558
Phase
PHASE2
Sponsor
Hackensack Meridian Health
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Lu-17-PSMA-617
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Patients age 18 or older.
  • Patients with histologically confirmed adenocarcinoma of the prostate.
  • Patients with high-risk disease defined as a preoperative prostate biopsy of Gleason Score 8 (GS8) (Grade group 4 \[GG4\]) or higher. Men with evid…
  • Pre-operative, pre-treatment PSMA scan with high expression in prostate confirmed by PET/CT 68Ga-PSMA-11 (greater than liver). Patients must not ha…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →